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Abst rac t
Introduction: Vaccine opponents indicate that the infant’s immune system is inadequately developed to handle 
multiple vaccines which may overwhelm the immune system, leading to allergic diseases.
Aim: To verify the association between the vaccine antigen overload derived from DTwP and the development of 
atopic sensitization and allergic diseases.
Material and methods: Data from an earlier established birth cohort in Krakow, followed up to the 6th year of life 
were used. Allergic diseases such as eczema, hay fever and asthma were diagnosed by a physician and reported 
every half a year from the 1st to 6th year of life by the child’s parent. Skin prick tests (SPT) were performed in children 
at 5 years of age. The data on infants’ vaccination were extracted from the physician’s records. The status of vaccine 
antigen exposure was based on different types of vaccines against pertussis (DTwP or DTaP) in a primary course. 
Results were determined by multiple logistic regression, adjusted to potential confounders.
Results: The analyzed population consisted of 234 children: 53.4% – boys and 46.6% – girls. Infants up to the age 
of 8 months were vaccinated with the primary course against pertussis, with DTwP – 60.7%, DTaP – 32.9% and 
further 6.4% with a mixed course (DTwP + DTaP). There were no significant relationships between any of vaccina-
tion groups and allergic disease and allergen sensitivity in the multiple logistic regression model with adjustment 
to potential confounders. 
Conclusions: The exposure to a large number of vaccine antigens derived from DTwP has no influence on the de-
velopment of allergic diseases and atopic sensitization in children. 
Key words: children, pertussis vaccine (whole-cell, acellular), atopic sensitization, allergic diseases.
Introduction
Immunization has an essential impact on public health 
worldwide. Numerous studies have shown the efficacy of 
different vaccines to protect children and adults from vari-
ous infectious diseases. However, some parents choose not 
to vaccinate their children for different reasons, such as 
doubts regarding their usefulness, philosophical or religious 
opinions and concerns over vaccine safety and efficacy [1]. 
Parents of children at a high risk of atopy are frequently 
concerned about the effect of immunizations in infancy. 
Apart from concerns about rare allergic reactions to the 
vaccine antigens or contaminants themselves, there exists 
a fear that immunizations may promote the development 
of allergic disease [2]. In addition, the rising prevalence of 
atopic disease today has been attributed to an introduction 
of the increasing number of recommended vaccines in im-
munization programs. The  concern of vaccine opponents 
is that the infant’s immune system is inadequately devel-
oped to handle vaccines safely or that multiple vaccines 
may overwhelm the immune system leading, among other 
things, to higher atopy sensitization and allergic diseases 
[3, 4]. In routinely recommended vaccines administered 
over the past 100 years, the whole cell pertussis vaccine 
(DTwP) contained the highest number of antigens among 
the other vaccines, including about 3000 of pertussis anti-
gens. The new, acellular pertussis vaccine (DTaP) consists of 
no more than 5 antigens (depending on the type of formu-
lation) [5]. In most of the developed countries, the replace-
ment of DTwP with DTaP allowed to significantly decrease 
the number of vaccine antigens in the recommended pro-
grams. Whereas previously recommended programs con-
sisted of more than 3000 antigens, nowadays including 
more kinds of vaccines, it consists of less than 150 antigens 
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(proteins and polysaccharides) [3]. Poland is the only one 
country in the European Union where infants are vaccinat-
ed with DTwP according to the mandatory immunization 
program. There is an access to DTaP as an alternative op-
tion, payable by infant’s parents. As a result of that strategy, 
about half of Polish infants are vaccinated with DTwP, and 
the rest of them with DTaP. That is why the exposure to the 
number of vaccine antigens varies significantly between 
those two groups of children. 
Aim
The aim of this study was to verify the hypothesis 
about the association between the vaccine antigen over-
load derived from DTwP and the subsequent develop-
ment of atopic sensitization and allergic diseases.
Material and methods
This is a prospective cohort study, combining environ-
mental monitoring and molecular approaches with com-
prehensive neurodevelopment and health assessments. 
In the analysis we used data from an earlier established 
birth cohort of children in Krakow, being part of the on-
going, collaborative study with the Columbia University 
in New York, on the vulnerability of fetus and child to 
environmental factors. This cohort was described in more 
detail in the previous publications [6, 7].
Briefly, the enrollment (3 November 2000 – 22 August 
2003) included only non-smoking women, aged 18–35 
years, with singleton pregnancy, without illicit drug use and 
HIV infection, free from chronic diseases such as diabetes 
or hypertension and residing in Krakow for at least one year 
prior to pregnancy. Children were followed up to the 6th year 
of life. Each year, mother or father were asked to provide in-
formation on infants’ health and household characteristics 
to trained interviewers, who carried out detailed, face-to-
face standardized interviews. Information on parental atopy 
was also collected. 
Vaccination data
The data on infants’ vaccination history (date of vac-
cination and type of vaccine) were extracted from the 
physician’s records when the children were 3 years old. 
The status of vaccine antigen exposure was based on dif-
ferent types of vaccines against pertussis (DTwP or DTaP) 
in a primary course (three vaccine doses up to 8 months 
of life). Children with longer vaccination delays (25%) were 
excluded from the study. Children’s vaccination status was 
divided into three groups:
– the vaccination course completed with DTwP included 
about 3000 pertussis antigens (manufactured in Po-
land by Biomed Krakow), 
– the vaccination course completed with DTaP included 
up to 5 pertussis antigens (Tripacel Sanofi Pasteur or 
Infanrix GlaxoSmithKline vaccines), 
– the mixed course (DTwP + DTaP). 
The exposure to other vaccines was similar in all 
three groups. Infants have been vaccinated according to 
the Polish vaccination schedule against hepatitis B and 
poliomyelitis, usually simultaneously with DTP. All of the 
used vaccines contained aluminum as an adjuvant.
Atopy
Allergic diseases such as eczema, hay fever and asth-
ma were diagnosed by a physician and reported every half 
a year from the 1st to 6th year of life by the child’s parent.
All skin prick tests (SPT) were performed when chil-
dren were 5 years old, using four common aeroallergens: 
Dermatophagoides pteronyssinus, Dermatophagoides fari-
nae, cat and dog hair. Additionally, in a smaller subsample, 
sensitization to mold as well as tree and grass pollens was 
also checked. The standardized extracts of allergens were 
used, including a positive and negative control solution. 
The technique of the tests was consistent with standards 
recommended by the European Academy of Allergy and 
Clinical Immunology. The tests were performed by trained 
nurses in one of out-patient allergy clinics. The results 
were read after 15 min by measuring the largest diam-
eter of the wheal. Sensitization status was interpreted as 
a positive when a wheal had the diameter of 3 mm and 
not smaller than the histamine control. 
Dosimetry of Pb in blood
Lead concentrations were examined in cord blood (at 
delivery) and in capillary blood (5-year-old children). Whole 
blood lead concentrations were determined using induc-
tively coupled plasma mass spectrometry CLIA’88 method 
“Blood lead cadmium mercury ICPMS_ITB001A”. This 
multi-element analytical technique is based on quadru-
pole ICP-MS technology [8]. More details on blood sample 
collection and analysis were presented in the earlier pub-
lications [7, 9].
Statistical analysis
Descriptive statistics were reported in a standard 
way (number and proportion; mean and/or median, and 
standard deviation). Exposure to DTP vaccine (see above) 
was categorized according to its type. Differences in the 
distribution of women’s and newborns’ parameters 
grouped by categorized DTP status were tested using χ2 
or Fisher’s exact test (for nominal variables) and one-way 
ANOVA or Kruskal-Wallis tests (for continuous variables).
Candidate confounding factors were selected based on 
the current literature. They include: gender, birth weight 
(continuous variable), parity, maternal age (continuous 
variable), education (university vs. non-university), mari-
tal status (married vs. unmarried) and poor economical 
status, maternal or paternal atopy, breastfeeding (child 
breastfed for at least 6 months), exposure to environmen-
tal tobacco smoking (ETS) prenatally and in a 6-year pe-
riod of life, presence of a dog or a cat at home for at least 
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a month in a 6-year period, indoor environment (presence 
of damp or mold at home) and blood lead level (cord blood 
and measurement at the age of 5 years). Maternal and 
paternal atopy was defined as reported medical diagnosis 
of eczema, atopic dermatitis, hay fever or food allergy. 
The candidate factors were first evaluated together 
with the type of DTP vaccination and were retained in 
further analyses only if they were statistically significant 
in a consistent way or influenced the course of DTP vac-
cination. In subsequent multivariable analyses, the set of 
confounding factors was further optimized, separately for 
each outcome. Associations were measured by multiple 
logistic regressions. Odds ratios were estimated either 
without any other factor than exposure (crude OR) or with 
the confounding factors (adjusted OR). Statistical analy-
ses were performed using SPSS 22.0 software.
Ethical approval
The parents of all children involved in the study gave 
their informed consent. The research protocol was ap-
proved by the Jagiellonian University Ethical Committee.
Results
The analyzed population consisted of 234 children: 
53.4% – boys and 46.6% – girls. Infants up to the age of 
8 months were vaccinated with a primary course against 
pertussis, with DTwP – 60.7%, DTaP – 32.9% and further 
6.4% with the mixed course (DTwP + DTaP).
As for study group characteristics, only maternal 
education, poor economical status, mother’s atopy and 
ETS exposure significantly differed in the primary course 
of DTP vaccination. Mothers who graduated from uni-
versity more often vaccinated their children with DTaP 
(63.6%) and infants of mothers with atopy were more 
likely to be vaccinated with the mixed course (40.0%). 
Infants prenatally exposed to ETS have been significantly 
more often vaccinated with DTwP in the primary course 
(45.1%) (Table 1). All of those confounders were included 
in multivariable analysis.
The frequency of allergic diseases and assessed 
sensitivity for the selected allergens did not differ sig-
nificantly between groups exposed to DTP in children 
at the age of 6 years. Hence, the cumulative incidence 
Table 1. Characteristics of the study subjects stratified by the type of primary course of DTP
Characteristic Total number DTwP DTaP Mixed course
(DTwP + DTaP)
P-value
Gender Boys 125 (53.4%) 72 (50.7%) 43 (55.8%) 10 (66.7%) 0.436
Girls 109 (46.6%) 70 (49.3%) 34 (44.2%) 5 (33.3%)
Parity 1 156 (66.7%) 87 (61.3%) 57 (74.0%) 12 (80.0%) 0.085
≥ 2 78 (33.3%) 55 (38.7%) 20 (26.0%) 3 (20.0%)
Gestational age < 37 weeks 5 (2.1%) 1 (0.7%) 4 (5.2%) 0 (0.0%) 0.104
Birth weight [g] 3420.1 ±469.56 3447.7 ±462.65 3376.8 ±487.17 3380.7 ±453.53 0.536
Birth length [cm] 54.7 ±2.78 54.7 ±2.79 54.6 ±2.89 54.8 ±2.21 0.932
Maternal university education 118 (50.4%) 64 (45.1%) 49 (63.6%) 5 (33.3%) 0.013
Mother’s age at 2nd trimester 27.5 ±3.61 27.3 ±3.73 28.2 ±3.46 26.7 ±2.92 0.130
Maternal marital status – married 219 (93.6%) 131 (92.3%) 73 (94.8%) 15 (100.0%) 0.610
Poor economical status 13 (5.6%) 12 (8.5%) 0 (0.0%) 1 (6.7%) 0.015
Breastfeeding up to 6 months 165 (70.5%) 98 (69.0%) 56 (72.7%) 11 (73.3%) 0.822
Maternal asthma 3 (1.3%) 1 (0.7%) 2 (2.6%) 0 (0.0%) 0.413
Maternal atopy 59 (25.2%) 28 (19.7%) 25 (32.5%) 6 (40.0%) 0.046
Paternal asthma 7 (3.0%) 5 (3.5%) 1 (1.3%) 1 (6.7%) 0.490
Paternal atopy 43 (18.4%) 26 (18.3%) 12 (15.6%) 5 (33.3%) 0.267
Atopy in any parent 86 (36.8%) 45 (31.7%) 32 (41.6%) 9 (60.0%) 0.055
Prenatal ETS 87 (37.2%) 64 (45.1%) 19 (24.7%) 4 (26.7%) 0.008
ETS during 6 years 48 (20.5%) 36 (25.4%) 11 (14.3%) 1 (6.7%) 0.060
Cord blood lead level [µg/l] 1.44 ±0.70 1.53 ±0.80 1.33 ±0.51 1.29 ±0.42 0.191
Blood lead level at the age of 5 [µg/l] 2.14 ±0.63 2.17 ±0.65 2.08 ±0.61 2.23±0.60 0.580
Pets at home 64 (37.0%) 33 (33.0%) 25 (41.7%) 6 (46.2%) 0.424
Mold indoors 60 (25.6%) 41 (28.9%) 16 (20.8%) 3 (20.0%) 0.371
Damp indoors 75 (32.1%) 48 (33.8%) 23 (29.9%) 4 (26.7%) 0.753
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of asthma, eczema and hay fever from the 1st to the 6th 
year of life was similar in the three pertussis vaccination 
groups (Table 2).
Our univariate analysis showed that only the expo-
sure to DTwP vs. DTaP was associated with a decreased 
risk of developing eczema in children (calculated for cu-
mulative incidence), (OR = 0.55; 95% CI: 0.31–0.99). There 
were no significant relationships between any of vaccina-
tion groups and allergic disease and allergen sensitivity 
in the multiple logistic regression model with adjustment 
for maternal education, poor economical status, moth-
er’s atopy, prenatal ETS, parity, breastfeeding, dwelling 
in damp or moldy conditions (Table 3). 
Discussion
In the present study, children vaccinated with DTwP 
were at a similar risk of atopic disorders as children vac-
cinated with DTaP. The burden of about 3000 antigens 
derived from DTwP on the infants’ immune system in 
comparison to 4 antigens included in DTaP had no influ-
ence on the development of allergic disease and atopic 
sensitization in children up to the 6th year of life. 
Our results did not confirm that the theoretical is-
sues, raised by many vaccination opponents, such as im-
mune “overload” by a great number of vaccine antigens 
in infancy is linked with a higher risk of allergy in chil-
dren [10]. We obtained the consistent results for all of the 
analyzed allergic diseases (eczema, hay fever, asthma), 
and performed tests for allergen skin sensitization. In 
the previous studies, there was inconsistent evidence 
for a relation between vaccination and the development 
of allergic disease. Usually most of the children are vac-
cinated and it is difficult to obtain adequate numbers of 
unvaccinated infants to examine the vaccination-allergic 
disease relationship. Hence, unvaccinated children are 
a highly selected and usually atypical group. It is related 
to studies on DTwP as well [11–14]. 
In our cohort, only 5 infants have not received routine 
vaccination and we excluded them from the study group 
to avoid the bias of medical and socio-economical con-
founders related to refraining from vaccination. There-
fore, we decided to calculate the relationship between 
the heavy burden of vaccine antigens derived from DTwP 
(about 3000 antigens) in comparison to the exposure to 
DTaP which included up to 5 antigens. That difference in 
the burden of vaccine antigens was sufficiently signifi-
cant to conduct our analysis. The rest of vaccine exposure 
was similar in the two study groups. We realize that the 
time of vaccination exposure is important in our analy-
sis and that period was limited up to the 8th month of 
life. Infants with a longer delay in primary DTP vaccina-
tion course have been excluded from the study cohort. 
The relatively short period of vaccination exposure and 
including in the analysis only the vaccinated children 
decreased the bias of reverse causation. The onset of 
allergic disease usually occurred after the vaccination 
exposure, and any earlier potential symptoms of allergy 
did not influence the immunization procedures because 
the entire cohort was vaccinated against pertussis. The 
crucial reasons for the vaccine choice (DTwP or DTaP) 
for infants were dependent on socio-economical factors 
which were included in the analysis as the important 
confounders. 
The previous studies about the relationship between 
DTwP exposure and allergy had compared vaccinated 
Table 2. Frequency of allergic diseases and allergen sensitivity stratified by the type of DTP course
Frequency Total DTwP DTaP Mixed course P-value
N % N % N % N %
Prevalence at the age of 6 years:
Asthma (n = 186) 11 5.9 8 7.4 2 3.1 1 7.7 0.446
Eczema (n = 186) 13 7.0 8 7.4 4 6.2 1 7.7 1.000
Hay fever (n = 186) 50 26.9 31 28.7 16 24.6 3 23.1 0.799
Any positive SPT: Dermatophagoides 
pteronyssinus, Dermatophagoides farinae, cat 
and dog dander (n = 162)
36 22.2 22 25.0 11 17.7 3 25.0 0.558
Any positive SPT: Dermatophagoides 
pteronyssinus, Dermatophagoides farinae, cat 
and dog dander, mold, tree and grass pollens 
(n = 97)
34 35.1 18 35.3 10 27.0 6 66.7 0.082
Cumulative incidence from the 1st to 6th year of life:
Asthma (n = 234) 22 9.4 11 7.7 8 10.4 3 20.0 0.283
Eczema (n = 234) 139 59.4 78 54.9 53 68.8 8 53.3 0.120
Hay fever (n = 234) 148 63.2 97 68.3 43 55.8 8 53.3 0.134
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groups with the unvaccinated one. The studies con-
ducted that way yielded inconsistent results. Our results 
are consistent with the observations of other authors 
who did not confirm the influence of DTwP exposure 
on the development of allergy [11, 15, 16]. Some of them 
even observed the protective effect of DTwP vaccination 
with respect to the onset of asthma and other allergic 
diseases in later life [17–19]. On the other hand, some 
other reports indicated the adverse effects of DTwP vac-
cination on the development of allergy [12, 20, 21]. That 
fact may result from the methodological differences 
in the epidemiological studies and the ascertainment 
bias linked with refraining from vaccination as well as 
the lack of data about the important confounders. The 
advantage of our study is its design – the prospective 
cohort study with reliable data on vaccination exposure, 
allergic disease onset and skin prick test results. We had 
a possibility to adjust the crude results to many plau-
sible confounders that could influence the development 
of allergy in early childhood. The advantage of our study 
is the active, long-term (9-year) survey of the study co-
hort. In this paper we decided to present the results of 
a 6-year survey, when children were administered with 
skin prick tests. The available data on allergic disease on-
set in children up to the 9th year of life gave us the pos-
sibility to calculate the same analysis for older children, 
as well. We obtained similar results like for the younger 
children – no relationship between DTwP exposure and 
the development of allergy. 
We realize that study on DTwP seems not so impor-
tant for the most of the developed countries because 
they removed that vaccine from their vaccination pro-
grams. Poland is the only country in the EU which still 
uses DTwP in its mandatory vaccination schedule. DTwP 
is relatively responsible for most of the adverse effects 
following immunization (AEFI) reported in Poland. Know-
ing the numbers of AEFI (observed up to 4 weeks after 
exposure), the Polish community is concerned about the 
long-term vaccine influence on children’s health. On the 
other hand, still using DTwP we had the possibility to 
test the hypothesis popular in the other countries of the 
“overload” of the immune system with vaccine antigens 
with respect to the development of allergy. DTwP expo-
sure affects the infant’s immune system with 10 times 
more antigens compared to the entire spectrum of other 
vaccines applied nowadays in vaccination programs of 
the developed countries [3]. Lack of the effects of DTwP 
exposure on the development of allergy indirectly indi-
cate that the cumulative number of antigens derived 
from the increasing number of new-generation vaccines, 
Table 3. Risk of allergic diseases and allergen sensitivity according to DTP vaccination status
Frequency Crude Adjusted*
OR (95% CI) P-value OR (95% CI) P-value
Prevalence at the age of 6 years:
Asthma (n = 186) DTwP vs. DTaP 2.52 (0.52–12.25) 0.252 2.54 (0.50–12.79) 0.258
DTwP vs. mixed course 0.96 (0.11–8.35) 0.970 1.25 (0.13–11.89) 0.844
Eczema (n = 186) DTwP vs. DTaP 1.22 (0.35–4.22) 0.754 1.56 (0.42–5.84) 0.508
DTwP vs. mixed course 0.96 (0.11–8.35) 0.970 0.82 (0.09–7.79) 0.866
Hay fever (n = 186) DTwP vs. DTaP 1.23 (0.61–2.49) 0.559 1.27 (0.60–2.67) 0.536
DTwP vs. mixed course 1.34 (0.35–5.21) 0.671 1.52 (0.36–6.45) 0.573
Any positive SPT: Dermatophagoides 
pteronyssinus, Dermatophagoides 
farinae, cat and dog dander (n = 162)
DTwP vs. DTaP 1.55 (0.69–3.48) 0.293 1.64 (0.69–3.89) 0.263
DTwP vs. mixed course 1.00 (0.25–4.03) 1.000 1.14 (0.26–4.97) 0.866
Any positive SPT: Dermatophagoides 
pteronyssinus, Dermatophagoides 
farinae, cat and dog dander, mold,  
tree and grass pollens (n = 97)
DTwP vs. DTaP 1.47 (0.58–3.72) 0.412 1.64 (0.61–4.44) 0.330
DTwP vs. mixed course 0.27 (0.06–1.22) 0.090 0.24 (0.05–1.15) 0.074
Cumulative incidence from the 1st to 6th year of life:
Asthma (n = 234) DTwP vs. DTaP 0.72 (0.28–1.88) 0.508 0.85 (0.31–2.30) 0.743
DTwP vs. mixed course 0.34 (0.08–1.37) 0.129 0.51 (0.11–2.27) 0.373
Eczema (n = 234) DTwP vs. DTaP 0.55 (0.31–0.99) 0.046 0.55 (0.30–1.03) 0.060
DTwP vs. mixed course 1.07 (0.37–3.10) 0.906 1.24 (0.40–3.82) 0.714
Hay fever (n = 234) DTwP vs. DTaP 1.70 (0.96–3.02) 0.068 1.78 (0.98–3.23) 0.060
DTwP vs. mixed course 1.89 (0.64–5.52) 0.247 1.97 (0.64–6.04) 0.236
*OR adjusted to parity, breastfeeding, maternal education, maternal atopy, poor economical status, prenatal ETS and indoor mold or damp.
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including usually only a few antigens, has no harmful in-
fluence manifested by an increased risk allergic diseases 
in children.
Conclusions
The exposure to a large number of vaccine antigens 
derived from DTwP has no influence on the development 
of allergic disease and atopic sensitization in children. The 
results of our study should not be treated as a supportive 
argument for the continuation of using DTwP which is 
responsible for too many AEFI in infants. They are further 
evidence on the vaccines safety which should encourage 
parents not to avoid or delay effective immunization of 
children, especially when weighed against the benefits.
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